Literature DB >> 3407455

Activation of the coagulation system in the subarachnoid space after subarachnoid haemorrhage: serial measurement of fibrinopeptide A and bradykinin of cerebrospinal fluid and plasma in patients with subarachnoid haemorrhage.

H Kasuya1, T Shimizu, T Okada, K Takahashi, T Summerville, K Kitamura.   

Abstract

Fibrinopeptide A (FPA) levels as an indicator of thrombin activity in the cerebrospinal fluid (CSF) and plasma of 25 patients with subarachnoid haemorrhage (SAH) were measured serially by radioimmunoassay (RIA). FPA levels in CSF were extremely high on days 0-1 (1253 +/- 269 ng/ml, mean +/- standard error) but decreased rapidly (11.3 +/- 3.9 ng/ml on days 2-4, 10.7 +/- 5.9 ng/ml on days 5-7, and 6.3 +/- 1.5 ng/ml on days 8-14). In the controls the FPA concentration in CSF was 1.2 +/- 0.9 ng/ml (mean +/- standard deviation). Plasma FPA levels in patients with SAH showed no statistically significant changes with time. The bradykinin (BK) concentration in CSF and plasma in 27 patients with SAH was measured serially by RIA. The concentrations in CSF were 122.7 +/- 22.7 pg/ml (mean +/- standard error) on day 0, 38.6 +/- 6.1 pg/ml on day 1, 22.7 +/- 6.3 pg/ml on day 2, and 17.1 +/- 3.0 pg/ml or less thereafter. Plasma BK levels in patients with SAH were higher than those in the control group, but there was no statistically significant change over time. From the measurement of FPA it was apparent that the coagulation system in the subarachnoid space is strongly activated in the early stage of SAH. The formation of BK in CSF after SAH is thought to be due to the contact activation of Hageman factor (intrinsic factor) in the subarachnoid space. Trabeculae as collagen bundles in the subarachnoid space were considered to have a possible role in activating the Hageman factor of the coagulation system in SAH.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3407455     DOI: 10.1007/bf01424566

Source DB:  PubMed          Journal:  Acta Neurochir (Wien)        ISSN: 0001-6268            Impact factor:   2.216


  25 in total

1.  Bradykinin, a hypotensive and smooth muscle stimulating factor released from plasma globulin by snake venoms and by trypsin.

Authors:  M ROCHA E SILVA; W T BERALDO; G ROSENFELD
Journal:  Am J Physiol       Date:  1949-02

2.  Studies on the interaction between collagen and a plasma kallikrein-like activity. Evidence for a surface-active enzyme system.

Authors:  P C Harpel
Journal:  J Clin Invest       Date:  1972-07       Impact factor: 14.808

3.  Ultrastructure of the arachnoid membrane in man.

Authors:  C A Lopes; W G Mair
Journal:  Acta Neuropathol       Date:  1974       Impact factor: 17.088

4.  Fibrinolytic activity of the cerebrospinal fluid after subarachnoid haemorrhage.

Authors:  D Tovi; I M Nilsson; C A Thulin
Journal:  Acta Neurol Scand       Date:  1973       Impact factor: 3.209

5.  Treatment of subarachnoid and other intracranial hemorrhages with proteinase inhibitors.

Authors:  F Sicuteri
Journal:  Ann N Y Acad Sci       Date:  1968-06-28       Impact factor: 5.691

6.  Inactivation of bradykinin in the pulmonary circulation.

Authors:  J W Ryan; J Roblero; J M Stewart
Journal:  Biochem J       Date:  1968-12       Impact factor: 3.857

7.  [Immunological study of late cerebral vasospasm in subarachnoid hemorrhage. Detection of immunoglobulins, C3, and fibrinogen in cerebral arterial walls by immunofluorescence method].

Authors:  T Hoshi; T Shimizu; K Kito; N Yamasaki; K Takahashi; M Takahashi; T Okada; H Kasuya; K Kitamura
Journal:  Neurol Med Chir (Tokyo)       Date:  1984-09       Impact factor: 1.742

8.  Coagulation and fibrinolytic activity of cerebrospinal fluid.

Authors:  M Anderson; K B Matthews; J Stuart
Journal:  J Clin Pathol       Date:  1978-05       Impact factor: 3.411

9.  The generation of fibrinopeptide A in clinical blood samples: evidence for thrombin activity.

Authors:  H L Nossel; M Ti; K L Kaplan; K Spanondis; T Soland; V P Butler
Journal:  J Clin Invest       Date:  1976-11       Impact factor: 14.808

10.  Actions of bradykinin on isolated cerebral and peripheral arteries.

Authors:  N Toda
Journal:  Am J Physiol       Date:  1977-03
View more
  7 in total

Review 1.  Brain ischemia in patients with intracranial hemorrhage: pathophysiological reasoning for aggressive diagnostic management.

Authors:  Daniel Naranjo; Michal Arkuszewski; Wojciech Rudzinski; Elias R Melhem; Jaroslaw Krejza
Journal:  Neuroradiol J       Date:  2013-12-18

Review 2.  Mechanisms of Global Cerebral Edema Formation in Aneurysmal Subarachnoid Hemorrhage.

Authors:  Erik G Hayman; Aaron Wessell; Volodymyr Gerzanich; Kevin N Sheth; J Marc Simard
Journal:  Neurocrit Care       Date:  2017-04       Impact factor: 3.210

3.  Administration of eptifibatide during endovascular treatment of ruptured cerebral aneurysms reduces the rate of thromboembolic events.

Authors:  Jacques Sedat; Yves Chau; Jean Gaudard; Laurent Suissa; Sylvain Lachaud; Michel Lonjon
Journal:  Neuroradiology       Date:  2014-10-18       Impact factor: 2.804

4.  Up-regulation of proteinase-activated receptor 1 and increased contractile responses to thrombin after subarachnoid haemorrhage.

Authors:  Y Maeda; K Hirano; Y Kai; M Hirano; S O Suzuki; T Sasaki; H Kanaide
Journal:  Br J Pharmacol       Date:  2007-09-03       Impact factor: 8.739

Review 5.  Is eptifibatide a safe and effective rescue therapy in thromboembolic events complicating cerebral aneurysm coil embolization? Single-center experience in 42 cases and review of the literature.

Authors:  Jacques Sedat; Yves Chau; Lydiane Mondot; Richard Chemla; Michel Lonjon; Bernard Padovani
Journal:  Neuroradiology       Date:  2013-11-27       Impact factor: 2.804

Review 6.  Prevention and treatment of thromboembolism during endovascular aneurysm therapy.

Authors:  Jens Fiehler; Thorsten Ries
Journal:  Klin Neuroradiol       Date:  2009-05-15

7.  The Dual Role of Kinin/Kinin Receptors System in Alzheimer's Disease.

Authors:  Bingyuan Ji; Qinqin Wang; Qingjie Xue; Wenfu Li; Xuezhi Li; Yili Wu
Journal:  Front Mol Neurosci       Date:  2019-10-01       Impact factor: 5.639

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.